Engineered immune cells take aim at tough lung cancer
NCT ID NCT05680922
First seen Apr 07, 2026 · Last updated May 26, 2026 · Updated 8 times
Summary
This early-phase trial tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells that carry a protein called DLL3. The study includes about 41 adults with advanced small cell lung cancer or related lung cancers that have not responded to standard treatments. The main goals are to find a safe dose and to see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Kentucky - Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.